HIMS slips as seller pressure weighs on near-term trend

HIMS slips as seller pressure weighs on near-term trend
Hims & Hers Health slides 5.44% today

Hims & Hers Health (HIMS) stock is trading at $17.55 after a decline of 5.44% on the day. The current price is positioned below its key short-term and long-term moving averages, underscoring persistent downward momentum.

HIMS price prediction
24H -0.35%
$17.29
48H 0.4%
$17.42
7D 1.27%
$17.57
1M -38.04%
$10.75
3M -53.43%
$8.08
6M -72.33%
$4.8
12M -59.14%
$7.09
Current price: $17.35 -0.1950 1.11%
Real-time Data 11:59
Daily range 17.15 Arrow from to Icon 18.54
Weekly range 17.15 Arrow from to Icon 20.44
Loading...

Highlights

  • Hims & Hers Health added FDA-approved obesity treatments like Zepbound to its telehealth offering, expanding its product range.
  • Investors now scrutinize subscriber retention rates and profitability outlook, increasing focus on business sustainability metrics.
  • Shares of Hims & Hers Health closed at $17.55, down 5.44%, with technical indicators showing persistent bearish momentum and a likely range of $15.89 to $19.21 for the next 2 to 3 days.

Profitability anxiety grows as new obesity drugs spotlight retention risk

Hims & Hers Health recently integrated FDA-approved obesity medications, such as Eli Lilly’s Zepbound, into its telehealth platform, according to News Jkn Co. This move has led investors to intensify their focus on the company’s subscriber retention rates and its path to profitability, reflecting underlying concerns regarding business execution and sustainability. The heightened scrutiny around these core metrics has contributed to increased uncertainty in the current trading environment.

Hims & Hers Health Inc. asset chart
Hims & Hers Health Inc. price dynamics. Source: TradingView.

Weakened structure and conflicting momentum limit upside near resistance

On the H1 timeframe, HIMS is trading below the H1 SMA-20 at $18.67 and below the H1 SMA-50 at $20, indicating that both the near-term and medium-term trend structures are under pressure. The price also remains beneath the D1 SMA-200 at $26.59, providing evidence of prolonged weakness in the broader structure. Immediate resistance is set by the Ichimoku Kijun at $18.76. Momentum indicators show MACD and ADX both in Sell mode, while Bull/Bear Power registers negative at -0.35, confirming intraday seller dominance. RSI is marking oversold territory, Stoch RSI and CCI are neutral, and the Awesome Oscillator is flat, resulting in mixed short-term momentum.

Elevated downside risk as range-bound setup persists near support

Over the next 2–3 sessions, HIMS is expected to trade within a typical volatility band of $15.89 to $19.21. The likelihood of a further move to the downside is elevated, with more than 80% probability, while any rebound toward resistance is less likely, with under 20% probability. If the price breaks above $18.76, a corrective rally could accelerate, but a drop through $15.89 would signal a renewed extension of the prevailing downtrend. Barring a decisive breakout, price action is likely to remain range-bound between these support and resistance levels.

Anton Kharitonov, analyst at Traders Union, sees Hims & Hers Health under strong technical and fundamental pressure. He notes that price remains below the H1 SMA-20 at $18.67, the H1 SMA-50 at $20, and the D1 SMA-200 at $26.59, with sellers maintaining dominance. Negative sentiment around subscriber retention and profitability, following the integration of obesity medications, adds to the bearish tone. "Until we see a sustained close above immediate resistance at $18.76 and improved business metrics, I remain defensive here."

Earlier, analysts noted that Hims & Hers Health was experiencing persistent downside momentum and technical weakness despite its recent strategic initiatives. The current setup builds on this view, with both intraday and broader timeframes signaling heightened downside risk, making a break below the $15.89 support level a pivotal event to monitor in the coming sessions.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.